Dated biotech reporting.
The FDA has granted interchangeability designation to Truxima (rituximab-abbs), Celltrion and Teva's biosimilar to Genentech's Rituxan, per the companies' July 1, 2026 announcement as reported by Goodwin. Truxima is the first rituximab biosimilar to receive interchangeable status in the United…
Gilead Sciences (Nasdaq: GILD) and Lakefront Biotherapeutics (Euronext and Nasdaq: LKFT) completed the acquisition of Ouro Medicines on June 4, 2026, with Gilead paying $1,675 million for all outstanding equity plus up to $500 million in contingent milestone payments, per the company's…
Parabilis Medicines, a startup developing peptide drugs for targets considered undruggable, raised $670 million in an initial public offering priced June 9, 2026, per BioPharma Dive's June 10 report — a record haul for a venture-backed biotech. The listing extends a 2026 streak in which 12 drug…
FDA has accepted Vertex's application for accelerated approval of povetacicept in adults with IgA nephropathy, with a decision date of November 30, 2026, the company announced June 1, 2026. The filing rests on a Phase 3 interim analysis showing a 52% reduction in urine protein-to-creatinine…
The FDA has approved Shionogi's Xocova (ensitrelvir) as the first oral post-exposure prophylaxis for COVID-19 in adults and adolescents 12 years of age and older, the company announced on June 1, 2026. The approval, covering use after contact with an individual who has COVID-19, came ahead of…